TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06604182: Phase 2a Proof-of-Concept Study of RAP-219 TARP-gamma-8 Selective AMPAR Negative Allosteric Modulator in Drug-Resistant Focal Epilepsy

Sponsor: rapport Therapeutics, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06604182 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06604182 Rescue Dossier →